A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application by Yeo, Tianrong et al.
1Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:12381  | https://doi.org/10.1038/s41598-020-69119-3
www.nature.com/scientificreports
A blood‑based metabolomics test 
to distinguish relapsing–remitting 
and secondary progressive 
multiple sclerosis: addressing 
practical considerations for clinical 
application
tianrong Yeo1,2, Megan Sealey1, Yifan Zhou1, Luisa Saldana3, Samantha Loveless4, 
timothy D. W. claridge5, Neil Robertson4, Gabriele DeLuca3, Jacqueline Palace3, 
Daniel c. Anthony1 & fay probert1*
The transition from relapsing–remitting multiple sclerosis (RRMS) to secondary progressive MS 
(SPMS) represents a huge clinical challenge. We previously demonstrated that serum metabolomics 
could distinguish RRMS from SPMS with high diagnostic accuracy. As differing sample-handling 
protocols can affect the blood metabolite profile, it is vital to understand which factors may influence 
the accuracy of this metabolomics-based test in a clinical setting. Herein, we aim to further validate 
the high accuracy of this metabolomics test and to determine if this is maintained in a ‘real‑life’ clinical 
environment. Blood from 31 RRMS and 28 SPMS patients was subjected to different sample-handling 
protocols representing variations encountered in clinics. The effect of freeze–thaw cycles (0 or 1) 
and time to erythrocyte removal (30, 120, or 240 min) on the accuracy of the test was investigated. 
For test development, samples from the optimised protocol (30 min standing time, 0 freeze–thaw) 
were used, resulting in high diagnostic accuracy (mean ± SD, 91.0 ± 3.0%). This test remained able to 
discriminate RRMS and SPMS samples that had experienced additional freeze–thaw, and increased 
standing times of 120 and 240 min with accuracies ranging from 85.5 to 88.0%, because the top 
discriminatory metabolite biomarkers from the optimised protocol remained discriminatory between 
RRMS and SPMS despite these sample-handling variations. In conclusion, while strict sample-handling 
is essential for the development of metabolomics-based blood tests, the results confirmed that the 
RRMS vs. SPMS test is resistant to sample-handling variations and can distinguish these two MS 
stages in the clinics.
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CPMG  Carr–Purcell–Meiboom–Gill
DMT  Disease-modifying therapies
EDSS  Expanded disability status scale
MRI  Magnetic resonance imaging
MRS  Magnetic resonance spectroscopy
MS  Multiple sclerosis
NMR  Nuclear magnetic resonance
OPLS-DA  Orthogonal partial-least square discriminant analysis
ppm  Parts per million
RRMS  Relapsing–remitting multiple sclerosis
SPMS  Secondary progressive multiple sclerosis
TOCSY  Total correlation spectroscopy
VIP  Variable importance in projection
The clinical transition from relapsing–remitting multiple sclerosis (RRMS) to secondary progressive MS (SPMS) 
represents a diagnostic challenge as progression is typically gradual and objective clinical signs often lag behind 
patient’s  symptoms1. While inflammation and neurodegeneration can occur continuously, clinically defined 
secondary progression often occurs in a non-uniform  manner2, whereby progression is interspersed with periods 
of relative clinical stability. There are currently no validated biofluid or imaging biomarkers that can reliably 
separate these two stages of  MS3 and, as a result, SPMS diagnosis can often only be made after observing progres-
sion of disability over a prolonged period of time, in some cases, years. As such, the diagnosis of SPMS is always 
established retrospectively when an irreversible accrual of disability has already  occurred3.
Metabolomics is an emerging approach for biomarker discovery in precision medicine and for identifying 
disease pathways underpinning clinical  phenotypes4,5. Metabolomics involves the comprehensive study of the 
metabolome; all low molecular weight (< 1,500 Da) metabolites within a biological sample. As metabolites are 
the biological end products of upstream processes involving gene and protein expression, the metabolome 
closely reflects the clinical phenotype and, thus, can provide valuable insight in to underlying pathological 
processes and identify novel biomarkers of disease. The majority of metabolomics studies in MS focus on the 
identification of blood-borne metabolite perturbations in MS patients relative to healthy controls using both 
nuclear magnetic resonance (NMR)-based6–8 and mass spectrometry-based  metabolomics9–12. While this is 
useful in aiding our understanding of MS disease activity as a whole, the distinction between MS and con-
trols is not a clinical diagnostic challenge. In contrast, relatively few studies have investigated the metabolite 
changes associated with the transition from RRMS to SPMS. We were the first to show, using serum 1H NMR 
metabolomics, that RRMS and SPMS can be  differentiated13 and highlighted the potential of this technique to 
objectively distinguish between these two phases of MS. Other studies have since followed suit, further validating 
the presence of distinct metabolic changes in SPMS relative to RRMS in cerebrospinal fluid (CSF) using mass 
spectrometry  methods15. In addition, a targeted mass spectrometry-based metabolomics study discovered that 
serum quinolinic acid levels were highest in primary progressive (PP) MS patients and decreased in SPMS and 
then RRMS patients  respectively16. Other studies have investigated both PPMS and SPMS patients to determine 
biomarkers in progressive disease, as a whole, relative to RRMS. In blood, perturbations in energy metabolism 
have been observed using HPLC metabolomics methods. While the metabolite changes identified correlated with 
EDSS and MRI measures of neurodegeneration, their diagnostic accuracy is not  known17,18. In CSF, a panel of 
250 proteins has been identified which is able to distinguish between RRMS and progressive (SPMS and PPMS 
combined) MS with an accuracy of 89.4% in a validation  cohort19. While such a test could be useful, monitoring 
of the transition from RRMS to SPMS in a clinical setting may be challenging due to the high cost of measuring 
large panels of proteins coupled with the invasive nature of CSF sampling. While our previous results coupled 
with the above reports provide evidence for the potential of metabolomics analysis in the diagnosis of MS, no 
studies have systematically investigated the tolerances of such diagnostic models in common clinical settings.
It is well known that metabolic alterations within blood samples can occur due to variations in pre-analytical 
sample-handling20–26. As a result, stringent processing and storage protocols are implemented in the initial 
(research) phase of metabolomics blood test  development27, which can be difficult to follow in clinical practice. 
While metabolic perturbations introduced by freeze–thaw and delayed centrifugation have been previously 
described in healthy  individuals20,21,23,24,26,28, there is a paucity of studies addressing how these factors may 
affect the accuracy of a diagnostic metabolomics test in a clinical environment. Indeed, the extent to which 
sample-handling variation affects overall diagnostic accuracy is likely to be disease and application specific, 
and dependent on the stability of the discriminatory metabolites identified. We have observed that at the John 
Radcliffe Hospital (Oxford, UK), samples were centrifuged within 4 h of collection with an average of 50 min. 
Therefore, to ensure that our RRMS vs. SPMS diagnostic test is applicable in a clinical setting, it is vital that the 
high diagnostic accuracy is maintained even in instances when the sample-handling protocol may vary. In this 
cross-sectional study, we further validate our metabolomics diagnostic test on an independent, prospective and 
well-characterised set of RRMS and SPMS samples (using the sample-handling protocol currently well-accepted 
in metabolomics) and investigate the impact of two of the most common sources of variation in sample-handling 
identified in our clinic: (1) freeze–thaw, and (2) delayed centrifugation.
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Methods
Subjects. Thirty-one RRMS patients and 28 SPMS patients were prospectively recruited from the Oxford 
University Hospitals Trust from November 2017 to July 2018. All patients recruited at Oxford were consented 
under the Oxford Radcliffe Biobank, approved by the NRES Committee South Central—Oxford C (REC refer-
ence: 09/H0606/5+5), and all research was performed in accordance with relevant guidelines and regulations.
In order, to determine the effect of long-term storage on metabolite concentrations, serum samples were 
requested from a cohort of 30 RRMS and 50 SPMS patients from the Welsh Neuroscience Research Tissue 
Bank, Cardiff University (REC reference: 19/WA/0058). These samples were stored at − 80 °C for between 1 and 
10 years. Patient information for this, additional, cohort can be found in Table S2.
All patients fulfilled the 2017 revisions to the McDonald criteria for  MS29. SPMS status was established clini-
cally by MS neurologists; all SPMS patients demonstrated progressive accrual of disability over at least 1 year 
independent of  relapses30, and had Expanded Disability Status Scale (EDSS) ≥ 4.5 at the time of confirmed dis-
ability  progression31,32. Clinical and demographic data were obtained from medical notes and patient interviews. 
Current EDSS was assessed on the day of recruitment, prior to blood sampling.
Blood collection, serum processing and NMR sample preparation. Blood was collected in BD 
Vacutainer tubes (BD 367837). The optimised sample-handling protocol is used frequently in metabolomics 
literature and involved the following  steps26,33: once collected, blood was left to stand for 30 min at room tem-
perature; blood was then centrifuged at 1,300×g for 10 min at room temperature for erythrocyte separation to 
obtain serum; serum was then immediately aliquoted and stored at − 80 °C until NMR sample preparation. For 
NMR sample preparation, serum was thawed at room temperature followed by ultra-centrifugation at 100,000×g 
for 30 min at 4 °C. 150 μL of the supernatant was then diluted with 400 μL of 75 mM sodium phosphate buffer 
prepared in  D2O (pH 7.4) and stored at − 80  °C until NMR analysis. Immediately before NMR analysis, the 
buffered NMR sample was thawed at room temperature and then transferred to a 5 mm borosilicate glass tube 
(Norell 502-7).
Variations of the optimised protocol. Three variations to the optimised protocol were introduced to 
resemble practical considerations encountered in the clinic and laboratory (Fig. 1). The freeze–thaw protocol 
was identical to the optimised protocol, but with an additional freeze–thaw to simulate a scenario whereby the 
NMR sample has already been prepared, but the NMR spectrometer was unavailable due to logistical or techni-
cal issues. The 120 min and 240 min protocols differed from the optimised protocol with 120 min and 240 min of 
standing time after venipuncture respectively before erythrocyte separation. These 2 protocol variations parallel 
a very common scenario whereby blood has been taken but not centrifuged in a timely manner due to man-
power demands in a busy clinic or laboratory. Apart from the protocol variations of interest, all other processes 
were kept strictly the same.
1H NMR metabolomics spectra acquisition. All NMR experiments were performed using a 700-MHz 
Bruker AVIII spectrometer. To reduce the possibility of ‘batch effect’ bias, samples from the four protocols and 
the different classes (RRMS and SPMS) were mixed/randomized throughout the NMR run and data acquired in 
Figure 1.  Flow diagram illustrating the sample-handling protocols investigated. The effect of freeze–thaw and 
increased standing time were investigated and compared to the ideal, optimised (30 min) protocol. Min minutes, 
NMR nuclear magnetic resonance.
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a blinded manner. To reduce inter-operator variability, all NMR samples were prepared by the same person. The 
same batch of reagents was used to prepare all samples. Four quality control samples were included throughout 
the run (one at the beginning, one at the end, and then at equal intervals throughout) to ensure reproducibility 
and minimal variation across spectra.
Technical details of the NMR experiments and data handling have been previously  published34. In brief, 1D 
1H (NMR) spectra were obtained using a Carr–Purcell–Meiboom–Gill (CPMG) pulse sequence which retains 
resonances from small molecular weight metabolites and mobile side chains of lipoproteins, while suppressing 
broad signals arising from large molecular weight serum components. The CPMG spectra were processed in 
Topspin (version 3.5, Bruker, Germany) followed by visual inspection to ensure precise referencing and baseline 
correction, and to check for spectral distortion or contamination. The processed spectra were then exported 
to ACD/Labs Spectrus Processor Academic Edition 12.01 (Advanced Chemistry Development, Inc., Toronto, 
Canada), whereby regions of the spectra between 0.80 and 4.20 parts per million (ppm) and 5.20–8.50 ppm were 
split into 0.02 ppm wide ‘bins’. Integral values of these spectral ‘bins’ were computed with sum normalisation and 
used as quantitative variables expressed in arbitrary units (AU). ‘Bins’ which contained no spectral resonances 
on visual inspection (i.e. noise) were excluded, as were ‘bins’ with a coefficient of variation exceeding 15% (cal-
culated across the quality control samples). In all, 185 metabolite ‘bins’ were available for supervised multivariate 
statistical analysis. Metabolite assignments were performed by referencing to literature values and the Human 
Metabolome  Database35. Further confirmation was done by inspection of the 2D pre-saturation correlation spec-
troscopy (COSY) spectra, spiking of known compounds, and 1D total correlation spectroscopy (TOCSY) spectra.
Univariate statistical analysis. All statistical analysis, apart from spectral analysis (see below), were per-
formed with STATA software (Release 14, College Station, TX: Statacorp LP) and GraphPad Prism (version 6, 
California, USA). Comparative analyses between RRMS and SPMS patients were performed using Mann–Whit-
ney U test or 2-sample t-test as appropriate for continuous variables, and with Chi squared test for categorical 
variables. Pearson’s or Spearman’s correlation was used to explore correlations depending on data normality. 
Repeated-measures 2-way ANOVA was used to explore potential interactions and Sidak’s test was applied for 
multiple comparisons. Two-tailed p values < 0.05 were considered statistically significant.
Multivariate statistical analysis. It should be noted that all OPLS-DA models presented here (whether 
developed using the optimal or sub-optimal sample-handing protocols) were validated on independent test data 
using external tenfold cross validation with repetition and permutation testing. No patient was included in both 
the training and test datasets simultaneously.
To identify metabolic differences and develop a multivariate diagnostic model between RRMS and SPMS, 
orthogonal partial-least square discriminant analysis (OPLS-DA) was performed on samples collected using the 
optimised protocol (recommended standard in the metabolomics field)34. All OPLS-DA models were thoroughly 
validated on independent test data using external tenfold cross-validation with repetition using in-house R 
scripts (R foundation for statistical computing, Vienna, Austria)36, and the ropls  package37. Ten-fold external 
cross-validation with 100 iterations was performed, creating an ensemble of 1,000 models. Further details of 
this approach have been previously  published34. In brief, this process involves repeated cycles of: (1) balancing 
class sizes, (2) random division of the spectral data into a training set (90% of data) and a test set (remaining 10% 
of data), (3) construction of OPLS-DA models using the training set alone, and (4) determining the predictive 
accuracy, sensitivity, and specificity of the OPLS-DA model using the independent test set. The validity of the 
metabolic separation between RRMS and SPMS was established if the mean predictive accuracy of the ensem-
ble (1,000 models) of model accuracies was significantly higher compared to the mean predictive accuracy of a 
separate ensemble (also 1,000 models) created by random class assignments on the same spectral data.
To determine how well the above diagnostic model developed performs on samples that have experienced 
freeze–thaw or increased standing time, the same external tenfold cross-validation strategy was employed with 
random subsets of the (1) freeze–thaw, (2) 120 min, and (3) 240 min samples selected as test sets. This replicates 
a scenario in which a diagnostic model developed on samples collected in a research setting is applied to samples 
collected in a clinical setting. No sample from the same patient existed in both the training and test sets simul-
taneously; i.e. the test set was always independent of the training set.
We also investigated whether samples collected with sub-optimal protocols can be used in a research setting 
to develop multivariate models and accurately identify metabolite biomarkers by using the OPLS-DA strategy 
described above, by using only samples from the freeze–thaw, 120 min, and 240 min protocols (in both training 
and test sets). Finally, we investigated whether samples stored long-term (up to 10 years) can be used to identify 
metabolite biomarkers by applying the same analytical strategy to a cohort of RRMS and SPMS patients from the 
Welsh Neuroscience Research Tissue Bank, Cardiff University (REC reference: 19/WA/0058). Direct comparison 
of the diagnostic accuracies and discriminatory metabolites identified by these models against the model devel-
oped using the optimised protocol provides valuable insight into the advantages and pitfalls of sample-handling 
variations for metabolomics analysis and biomarker identification.
ethics approval and consent to participate. This study was approved by the Oxford Radcliffe Biobank 
(NRES Committee South Central—Oxford C, REC reference: 09/H0606/5+5) and the Welsh Neuroscience 
Research Tissue Bank, Cardiff University (REC reference: 19/WA/0058). All patients gave their (written) 
informed consent to participate in the study.
consent for publication. The consent for publication was given by all authors.
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Results
clinical characteristics of study cohort. Thirty-one RRMS patients and 28 SPMS patients were recruited 
into the study. As expected, SPMS patients were older, had longer disease duration, lower annualised relapse rate 
(ARR) in the previous 2 years, higher EDSS, and none were on disease-modifying therapies (DMT) (Table 1). No 
differences in gender were observed, with a preponderance of females in both groups.
Blood samples from the optimised protocol result in well-validated OPLS-DA models with a 
mean predictive accuracy of 91.0%. In order to validate our previous results using a new independent 
cohort, samples collected using the optimised protocol (recommended protocol in metabolomics literature) were 
used to construct discriminatory OPLS-DA models to segment RRMS from SPMS (i.e. both training and test 
data from the optimised protocol). The representative OPLS-DA scores plot showed excellent separation between 
RRMS and SPMS patients (Fig. 2A). The mean predictive accuracy for the ensemble of the OPLS-DA models of 
RRMS vs. SPMS was significantly higher than the mean predictive accuracy of the ensemble created by random 
class assignments (mean ± SD, 91.0 ± 3.0% vs. 47.8 ± 9.5%; p < 0.001) (Fig. 2B). Sensitivity and specificity indices 
can be found in Table S1. One SPMS patient lies towards the boundary of the RRMS region of the OPLS-DA 
scores plot (Fig. 2). This patient was diagnosed as SPMS at the time of blood sample collection and her EDSS was 
4.5. As a result, it is possible that the positioning of this sample in the scores plot represents the metabolic profile 
of early progressive disease and, potentially, the transition from RRMS to SPMS. Ongoing work, investigating 
serial samples of patients transitioning from RRMS to SPMS will elucidate this further.
To identify the most discriminatory metabolites driving the distinction between RRMS and SPMS, vari-
able importance in projection (VIP) scores were generated. The VIP score is a measure of the importance of a 
metabolite in the OPLS-DA model; the higher the VIP score, the greater the contribution a metabolite makes to 
the  model37. Seven metabolites were identified as highly discriminatory; the VIP cutoff of 1.48 was obtained by 
identifying the inflexion point in the VIP ranking plot (Fig. S1). Details of these 7 discriminatory metabolites 
are shown in Table 2. In summary, lipoproteins, choline and 3-hydroxybutyrate are lower in SPMS compared to 
RRMS, while glucose and N-acetylated glycoproteins/glycolipids are higher. These discriminatory metabolites, 
and indeed their directions, are consistent with observations from our previous  cohort13, providing strong evi-
dence that the identified metabolites are biomarkers of MS disease stage.
Potential confounders do not account for the metabolic separation between RRMS and 
SPMS. We explored if baseline differences between RRMS and SPMS patients could account for their meta-
bolic separation. Firstly, there were no strong correlations (i.e. all  R2 < 0.3) of any of the discriminatory metabo-
lites with age, disease duration, number of relapses in the last 2 years, EDSS, body mass index (BMI), time from 
last meal, or number of units of alcohol consumed per week, and there were no significant associations between 
any of the metabolites with comorbidity status. Within RRMS patients, there were no differences in any of the 
metabolite levels stratified by DMT status. Secondly, investigation of the OPLS-DA scores plot revealed no clus-
tering of the potential confounders (expressed as binary variables) confirming no confounding effect (Fig. S2). 
Importantly, RRMS patients who were ≥ 50 years old or had EDSS ≥ 6.0 did not cluster near to the SPMS patients, 
and RRMS patients on DMT were spread throughout the RRMS cluster including those nearest to the SPMS 
cluster. Patients with BMI ≥ 30, consumed ≥ 1 units of alcohol per week, and were fed or fasted were also evenly 
distributed across both groups. Smoking was not explored as a confounder as there were only 3 current smokers 
in the entire cohort.
Table 1.  Clinical and demographic characteristics of the study cohort. ARR annualised relapse rate, BMI 
body mass index, DMT disease modifying therapy, EDSS Expanded Disability Status Scale, RRMS relapsing–
remitting MS, SD standard deviation, SPMS secondary progressive MS. a ARR calculated only if disease 
duration is at least 2 years.
RRMS (n = 31) SPMS (n = 28) p value
Age (years,) mean ± SD 43.5 ± 9.7 58.1 ± 9.6 < 0.001
Female, no. (%) 23 (74.2) 20 (71.4) 0.811
Disease duration (years), median (range) 9.2 (0.8–24.2) 26.6 (3.9–50.3) < 0.001
ARR a last 2 years, median (range) 0.0 (0.0–1.5) 0.0 (0.0–0.0) < 0.001
Time since last relapse (months), median (range) 23.8 (0.92–142.9) – –
EDSS, median (range) 2.5 (1.0–6.5) 7.0 (4.5–8.5) < 0.001
DMT use, no. (%) 20 (64.5) 0 (0.0) < 0.001
 Glatiramer acetate 8 (25.8) – –
 Interferon beta 2 (6.5) – –
 Dimethyl fumarate 7 (22.6) – –
 Fingolimod 1 (3.2) – –
 Natalizumab 1 (3.2) – –
 Alemtuzumab 1 (3.2) – –
BMI, mean ± SD 25.9 ± 4.6 28.0 ± 5.9 0.132
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The well-validated OPLS-DA model is resistant to variations in sample-handling and is still 
able to stage MS accurately. Next, we explored if the high predictive accuracy of our well-validated 
model (Fig.  2) is maintained when the handling of samples is sub-optimal, i.e. increasing standing time, or 
an additional freeze–thaw. This is akin to developing a metabolomics blood test using stringent samples (in a 
research setting) and then applying the test in a clinical setting. The well-validated OPLS-DA models were able 
to predict the diagnosis of samples from the freeze–thaw, 120 min, and 240 min protocols with accuracies of 
85.5 ± 3.8%, 85.9 ± 3.1%, and 88.0 ± 3.0% respectively (Fig. 3). This translates to a relative accuracy reduction of 
6.0%, 5.6% and 3.3% respectively, when compared to using optimised protocol samples as the test set. Sensitivity 
and specificity indices can be found in Table S1. Of note, samples left standing for 120 min and 240 min after 
venipuncture maintained very high specificities for SPMS (94.0% and 93.0% respectively), allowing SPMS to be 
‘ruled in’.
Figure 2.  Performance of the OPLS-DA models generated using samples from the optimised sample-handling 
protocol. (A) The representative OPLS-DA scores plot of this well-validated model illustrates a distinct 
separation between RRMS and SPMS patients, (B) with a high predictive accuracy of 91.0 ± 3.0%. Each point 
in the scores plot represents all metabolomics spectral data from 1 patient condensed into a single data point. 
Points (i.e. patients) located closer to one another on the scores plot are metabolically more similar than those 
further apart. OPLS-DA orthogonal partial-least square discriminant analysis, RRMS relapsing–remitting MS, 
SPMS secondary progressive MS. Kolmogorov Smirnov test, ***p < 0.001.
Table 2.  The identified discriminatory metabolites from the well-validated OPLS-DA model. HDL high 
density lipoprotein, LDL low density lipoprotein, NAC N-acetyl-cysteine, OPLS-DA orthogonal partial-least 
square discriminant analysis, RRMS relapsing–remitting MS, SPMS secondary progressive MS, VIP variable 
importance in projection, VLDL very low density lipoprotein.
Discriminatory metabolites
Chemical shift of contributing spectral ‘bins’ (VIP 
score, VIP rank) Fold change in SPMS relative to RRMS
Mobile –CH3 HDL/LDL
0.80….0.82 ppm (2.15, 8)
0.82….0.84 ppm (3.10, 5)
0.84….0.86 ppm (4.29, 1)
0.86….0.88 ppm (2.52, 6)
0.83
3-Hydroxybutyrate 1.20….1.22 ppm (2.07, 10) 0.84
Mobile (–CH2–)n LDL
1.22….1.24 ppm (3.24, 4)
1.24….1.26 ppm (3.46, 3) 0.84
Mobile (–CH2–)n Chylomicron/VLDL 1.26….1.28 ppm (2.12, 9) 0.92
NAC1/=CH–CH2–CH2– 2.04….2.06 ppm (1.48, 12) 1.07
Mobile –N(CH3)3/free Choline
3.20….3.22 ppm (2.38, 7)
3.22….3.24 ppm (3.69, 2) 0.86
Glucose 3.88….3.90 ppm (1.50, 11) 1.07
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While serum metabolite concentrations vary as a result of sample-handling, the identified 
metabolite biomarkers remain discriminatory for RRMS and SPMS. Next, to explore if the 7 dis-
criminatory metabolites identified by our well-validated model (Fig. 2) remained discriminatory with sub-opti-
mal protocols, repeated-measures 2-way ANOVA (the 2 factors being MS subtype and protocol variation) was 
performed. All metabolites remained discriminatory with variations in standing time (Fig. 4A), while most were 
still able to distinguish RRMS vs. SPMS despite an additional freeze–thaw (Fig. 4B). There was no interaction 
between MS subtype with any of the protocol variations within all the metabolite biomarkers indicating that the 
differences in metabolite levels between RRMS and SPMS are similar despite sample-handling variations, and 
analogous metabolic perturbations occur in RRMS and SPMS sera.
Using samples collected under sub‑optimal protocols for model development reduces predic‑
tive accuracies. Next, we explored if samples from the optimised protocol are strictly required for metabo-
lomics test development, or if samples from sub-optimal protocols could be utilised for this purpose. OPLS-DA 
models developed (and validating by tenfold cross-validation and permutation testing) using samples within 
the freeze–thaw, 120 min and 240 min protocols (as both training and test sets) resulted in predictive accura-
cies of 89.6 ± 3.3%, 81.7 ± 3.5% and 84.9 ± 3.2% respectively (Fig. 5A). As the effect of sample-handling condi-
tions on the top discriminatory metabolites was only modest, the top 5 discriminatory metabolites selected by 
each model were the same (Fig. S3). Due to the significant impact of freeze–thaw on glucose and NAC1 levels, 
these metabolites were ranked significantly lower in the ‘freeze–thaw model’. There was no advantage to using 
a combination of samples from the optimised protocol and sub-optimal protocols (optimised/freeze–thaw, opti-
mised/120  min, optimised/240  min, optimised/freeze–thaw/120  min/240  min) for test development (Fig.  5B). 
Indeed, using a combination of all protocols for model development (representing a scenario with highly vari-
able sample-handling) resulted in a significant decrease in diagnostic accuracy to 71.9 ± 6.3%. Sensitivity and 
specificity indices for all models can be found in Table S1.
As previous studies have reported significant alterations in serum metabolite concentrations as a result of 
long-term (> 5 years) storage at − 80 °C38,39, we investigated whether biobanked samples could be used for model 
development. To this end, we used RRMS and SPMS samples obtained from the Welsh Neuroscience Research 
Tissue Bank which were stored at − 80 °C for between 1 and 10 years (Table S2). OPLS-DA models built using 
samples stored for between 1 and 10 years resulted in a predictive accuracy of only 58%. Although this accuracy 
is significantly greater than expected by random chance, as confirmed by permutation testing, this does not rep-
resent sufficient predictive accuracy for use in a clinical setting. As none of the potential demographic and clinical 
confounders investigated significantly impacted the metabolite biomarkers identified (Fig. S2), the decrease in 
diagnostic accuracy observed using the biobanked samples is not a result of differences between the cohorts but 
rather a result of long-term storage of the samples. Indeed, significant alterations in metabolite concentrations 
were observed in samples stored at − 80 °C for > 5 years compared to those stored for ≤ 5 years (Fig. S4). Further-
more, when only biobanked samples stored for ≤ 5 years were used for diagnostic test development, the accuracy 
improved to 66%. In contrast, our well-validated OPLS-DA model (Fig. 2, trained using optimal samples) was 
still able to diagnose (RRMS vs. SPMS) biobanked samples up to 5 years old with an accuracy of 66%, although 
the accuracy drops to 39% when predicting the diagnosis of samples stored for > 5 years. These results confirm 
that biobanked samples can be used for metabolite biomarker discovery in a research setting (although samples 
collected under optimal conditions should be used for clinical test development).
Figure 3.  Box plots illustrating the diagnostic accuracy of the well-validated discriminatory RRMS vs. SPMS 
OPLS-DA model on sub-optimal samples, which have undergone freeze–thaw or increased standing time of 
120 min and 240 min. Min minutes, OPLS-DA orthogonal partial-least square discriminant analysis, RRMS 
relapsing–remitting MS, SPMS secondary progressive MS. Comparative analysis was performed using one-way 
ANOVA with Tukey’s post-hoc corrections. ***p < 0.001.
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Discussion
In this study, using an improved metabolomics algorithm on a prospective cohort of RRMS and SPMS patients, 
we were able to stage MS with 91% accuracy and the metabolite biomarkers identified agree with those in 
our previous work. We also introduced commonly encountered sample-handling variations to ‘stress-test’ our 
metabolomics algorithm and observed only a modest decrease in accuracy. Our current study supports the 
clinical applicability of this metabolomics test, by (1) further validating our results on an independent cohort, 
(2) confirming that the identified metabolite biomarkers remain discriminatory despite variations in sample-
handling, and, thus, demonstrating that (3) samples collected prospectively from a ‘real-world’ setting are accu-
rately diagnosed by our models.
The transition from RRMS to SPMS is phenotypically gradual and clinicians often diagnose SPMS much later 
(the mean period of diagnostic uncertainty was 2.9 years in one study) when there is clear sustained accumulation 
of  disability1. Therefore, the diagnosis of SPMS is retrospective and further aggravated by a lack of consensus 
on clinical  definitions31. As the paradigm of MS treatment shifts towards halting progression instead of merely 
reducing relapses, there is an urgent need for molecular biomarkers to objectively confirm SPMS and to monitor 
disease progression. Our approach has the potential to identify the onset of progression for clinical management 
purposes, as well as provide robust inclusion criteria for entry into SPMS clinical trials. Moreover, the use of 
Figure 4.  The effect of (A) increasing standing time, and (B) freeze–thaw on the identified serum metabolite 
biomarkers distinguishing RRMS (black circle) and SPMS (green diamond). HDL high density lipoprotein, LDL 
low density lipoprotein, Min minutes, NAC N-acetyl-cysteine, RRMS relapsing–remitting MS, SPMS secondary 
progressive MS, VIP variable importance in projection, VLDL very low density lipoprotein. Repeated measures 
2-way ANOVA was performed with Sidak’s post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.001. +Statistically 
significant from multivariate OPLS-DA. Error bars represent standard error of the mean.
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serum allows serial samples to be taken for prospective monitoring of both the onset and rate of progression. 
Although we would recommend that blood samples are processed within 30 min of collection, immediately 
aliquoted, and stored at − 80 °C until analysis for model development and validation, accurate results are still 
obtained using samples collected in a clinical setting. Furthermore, samples stored for > 5 years can still provide 
significant and useful results for biomarker discovery in a research setting, although care should be taken as 
serum metabolite concentrations may change.
While the principal advantage of our multivariate analysis is to identify disease-specific metabolic signatures 
(i.e. combination of all metabolites), we were also able to discern specific discriminatory metabolites distin-
guishing RRMS and SPMS; higher lipoproteins, choline, 3-hydroxybutyrate in RRMS, and higher glucose and 
N-acetylated glycoproteins/glycolipids in SPMS. These are remarkably consistent (in terms of their importance 
and direction) across our current and previous cohorts, and may provide further clues to disentangle the neu-
roinflammatory and neurodegenerative processes that are present in the two MS disease phases, though to vary-
ing degrees. Indeed, recent NMR lipidomics studies have reported on the differences in lipoprotein subclasses 
and their immunomodulatory functions between RRMS, SPMS and age-gender matched healthy  controls40,41. 
Our findings of higher 3-hydroxybutyrate and lower glucose in RRMS patients also parallel the observations of 
another NMR metabolomics study comparing MS patients (84% of whom were RRMS) and healthy  controls7. 
Taking these findings in totality, these metabolites could provide inference to the pro-inflammatory state within 
RRMS. While there have been no studies reporting differences in blood choline levels between RRMS and 
progressive MS patients, 1H NMR studies have found increased choline (in both CSF and blood) in RRMS with 
respect to healthy controls as well as to non-MS  controls7,42. Our finding of higher serum choline in RRMS may 
suggest higher myelin turnover (increased myelin breakdown and/or failure to synthesise myelin), as demon-
strated by brain magnetic resonance spectroscopy (MRS) studies showing higher choline levels in RRMS patients 
compared to  controls43–45.
We acknowledge that the remarkable accuracy achieved in distinguishing RRMS from SPMS in this study 
could be in part due to recruiting patient groups that are phenotypically more distinct along the continuum of 
MS disease course. However, patients with unequivocal SPMS status (and indeed RRMS) were required to allow 
us to construct the most discriminatory models and to use these to explore the accuracy changes arising from 
protocol variations. Furthermore, we did not find any potential confounders accounting for the metabolic dif-
ferences between RRMS and SPMS patients despite extensive analyses. In particular, there was no association 
between any of the identified metabolites and age. Approximately 50–60% of RRMS patients will go on to develop 
SPMS about 20 years after disease  onset46,47, therefore the older age in the SPMS group is a natural corollary 
rather than a bias in patient recruitment. There were no strong correlations of any of the top discriminatory 
metabolites with age, and indeed of the individual metabolite ‘bins’ with age (the highest  R2 was 0.22). Stratifica-
tion of our study cohort into 2 age groups, < 50 years and ≥ 50 years old, revealed no clustering on the OPLS-DA 
scores plot (Fig. S2A). In particular, RRMS patients who were ≥ 50 years old were evenly distributed throughout 
the RRMS cluster. These 2 approaches suggest that age is not a confounding factor in the metabolic distinction, 
both in terms of the individual discriminatory metabolites as well as the global metabolic profile, between these 
2 MS stages. We also recognise the relatively small cohort size in our study as a possible limitation. However, 
the results presented reproduce our previous published results on independent patients adding substantial to 
weight to the validity of the biomarkers  identified13,14. It should be noted that this is still the second largest 
cohort to be studied by serum NMR  metabolomics13 and the third largest cohort with a robust and well-defined 
Figure 5.  (A) Box plots of OPLS-DA model predictive accuracies using samples within each protocol as both 
the training and test sets. (B) Box plots of OPLS-DA model predictive accuracies using combinations of samples 
from the optimised protocol and from sub-optimal protocols as both the training and test sets. Min minutes, 
OPLS-DA orthogonal partial-least square discriminant analysis. Comparative analysis was performed using one-
way ANOVA with Tukey’s post-hoc corrections. *p < 0.05, ***p < 0.001.
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sample-handling protocol to investigate metabolomic differences between RRMS and SPMS by any metabolomics 
 modality18. Other studies with larger cohorts have been performed using mass spectrometry methods, but these 
studies did not specify their sample-handling protocol, which is likely to vary due to the inclusion of samples 
from multiple centres and  biobanks16,17. Furthermore, while these studies investigated larger cohorts overall, 
the number of SPMS patients in both reports is lower than presented here. Thus, this study represents, to date, 
the only simultaneous comparison of rigorously controlled sample-handling procedures from samples from a 
single blood draw, in a patient population.
conclusion
There is an unmet need for biofluid markers to differentiate these two phases of MS. Our study showed that RRMS 
and SPMS can be distinguished with high accuracy using serum metabolomics, and the accuracy our RRMS 
vs. SPMS test remained robust to variations in sample-handling encountered in the clinics. Future work will 
determine how the well-validated model performs on a large prospective cohort of patients that includes patients 
suspected to be transitioning to SPMS. Serial samples from these ‘transitional’ patients coupled with detailed 
clinical follow-up will determine the diagnostic accuracy of the test in a clinical setting, and these samples could 
also be used to model progression to allow predictive models to be constructed.
Data availability
The metabolomics and clinical datasets, as well as supporting data generated and analysed during the current 
study are available to any qualified investigator from the corresponding author on reasonable request. Raw data 
files can be accessed through the Metabolights open access database (Study ID MTBLS1712).
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